DOCSLIB.ORG

Hetlioz, INN-Tasimelteon

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hetlioz, INN-Tasimelteon 23 April 2015 EMA/CHMP/601383/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Hetlioz International non-proprietary name: tasimelteon Procedure No. EMEA/H/C/003870/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union Administrative information Name of the medicinal product: Hetlioz Applicant: Vanda Pharmaceuticals Ltd. Liberty House 222 Regent Street London, W1B 5TR United Kingdom Active substance: tasimelteon International Nonproprietary Name/Common tasimelteon Name: Pharmaco-therapeutic group Psycholeptics, melatonin receptor agonists (ATC Code): (N05CH03) Therapeutic indication: Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults. Pharmaceutical form: Capsule, hard Strength: 20 mg Route of administration: Oral use Packaging: bottle (HDPE) Package size: 30 capsules EMA/CHMP/601383/2014 Page 2/79 Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ..................................................................................... 7 1.2. Manufacturers ..................................................................................................... 8 1.3. Steps taken for the assessment of the product ........................................................ 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction ........................................................................................................ 9 2.2. Problem statement ............................................................................................... 9 2.3. About the product .............................................................................................. 10 2.4. Quality aspects .................................................................................................. 10 2.4.1. Introduction.................................................................................................... 10 2.4.2. Active Substance ............................................................................................. 10 2.4.3. Finished Medicinal Product ................................................................................ 12 2.4.4. Discussion on chemical, pharmaceutical and biological aspects.............................. 14 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 14 2.5. Non-clinical aspects ............................................................................................ 15 2.5.1. Introduction.................................................................................................... 15 2.5.2. Pharmacology ................................................................................................. 15 2.5.3. Pharmacokinetics ............................................................................................ 17 2.5.4. Toxicology ...................................................................................................... 19 2.5.5. Ecotoxicity/environmental risk assessment ......................................................... 29 2.5.6. Discussion on non-clinical aspects ..................................................................... 30 2.5.7. Conclusion on the non-clinical aspects ............................................................... 32 2.6. Clinical aspects .................................................................................................. 32 2.6.1. Introduction.................................................................................................... 32 2.6.2. Pharmacokinetics ............................................................................................ 34 2.6.3. Pharmacodynamics .......................................................................................... 39 2.6.4. Discussion on clinical pharmacology ................................................................... 39 2.6.5. Conclusions on clinical pharmacology ................................................................. 40 2.7. Clinical efficacy .................................................................................................. 41 2.7.1. Dose response studies ..................................................................................... 41 2.7.2. Main studies ................................................................................................... 42 2.7.3. Discussion on clinical efficacy ............................................................................ 61 2.7.4. Conclusions on the clinical efficacy .................................................................... 63 2.8. Clinical safety .................................................................................................... 63 2.8.1. Discussion on clinical safety .............................................................................. 68 2.8.2. Conclusions on the clinical safety ...................................................................... 69 2.9. Pharmacovigilance ............................................................................................. 69 EMA/CHMP/601383/2014 Page 3/79 2.10. Risk Management Plan ...................................................................................... 70 2.11. Product information .......................................................................................... 76 2.11.1. User consultation ........................................................................................... 76 3. Benefit-Risk Balance ............................................................................. 76 4. Recommendations ................................................................................. 78 EMA/CHMP/601383/2014 Page 4/79 List of abbreviations ADR Adverse Drug Reaction AE Adverse Event ALT Alanine aminotransferase aMT6s urinary 6-sulfatoxymelatonin ANCOVA analysis of covariance AST aspartate aminotransferase AUS area under the plasma concentration-time curve AUC0-24 AUC from time 0 to 24 hours AUC0-inf AUC from time 0 extrapolated to infinity BCS Biopharmaceutical Classification System BMI Body Mass Index CEP Certificate of Suitability CGI-C Clinical Global Impression of Change CHMP Committee for Medicinal Products for Human Use Cmax maximum observed plasma concentration Cmin minimum observed serum concentration CYP cytochrome P-450 DSC Differential scanning calorimetry dTSD Day time Total Sleep Duration EC European Commission EEA European Economic Area EU European Union GC Gas chromatography GCP Good Clinical Practice GMP Good Manufacturing Practice HDPE High Density Polyethylene HPLC High-performance liquid chromatography ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICP-MS Inductively coupled plasma mass spectrometry ITT Intent to treat IR Infrared KF Karl Fischer titration LC-MS Liquid Chromatography coupled with Mass Spectrometry LDPE Low Density Polyethylene LOD Limit of Detection LOQ Limit of Quantification LQ-nTST Lower Quartile of nTST MoST Midpoint of Sleep Timing n/a not applicable Non-24 Non-24-Hour Sleep-Wake Disorder N24CRS Non-24 Clinical Response Scale nTST Night-time Total Sleep Time PhEur European Pharmacopoeia PIL Patient Information LeafletPIP Paediatric Investigation Plan EMA/CHMP/601383/2014 Page 5/79 PK Pharmacokinetic PP polypropylene Pre-SQ Pre-Sleep Questionnaire PVC polyvinyl chloride RH relative humidity SAE Serious Adverse Event SCN suprachiasmatic nucleus SmPC Summary of Product Characteristics TSE Transmissible Spongiform Encephalopathy Tmax time at maximum concentration UQ-dTSD Upper Quartile of dTSD UV Ultraviolet XRPD X-ray powder diffraction EMA/CHMP/601383/2014 Page 6/79 1. Background information on the procedure 1.1. Submission of the dossier The applicant Vanda Pharmaceuticals Ltd. submitted on 1 May 2014 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Hetlioz, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 24 October 2013. Hetlioz was designated as an orphan medicinal product EU/3/10/841 on 23 February 2011. Hetlioz was designated as an orphan medicinal product in the following indication: treatment of Non-24-Hour Sleep-Wake Disorders in blind people with no light perception. The applicant applied for the following indication: treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in the totally blind. Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Hetlioz as an orphan medicinal product in the approved indication. The outcome of the COMP review can be found on the Agency's website: ema.europa.eu/Find medicine/Rare disease designations. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application. The applicant indicated that tasimelteon was considered to be a new active substance. The application submitted is composed of administrative
Load more

Recommended publications
  • Evaluation of Depression and Anxiety, and Their Relationships with Insomnia, Nightmare and Demographic Variables in Medical Students
    Sleep Hypn. 2019 Mar;21(1):9-15 http://dx.doi.org/10.5350/Sleep.Hypn.2019.21.0167 Sleep and Hypnosis A Journal of Clinical Neuroscience and Psychopathology ORIGINAL ARTICLE Evaluation of Depression and Anxiety, and their Relationships with Insomnia, Nightmare and Demographic Variables in Medical Students Alireza Haji Seyed Javadi1*, Ali Akbar Shafikhani2 1MD. of Psychiatry, Associate Professor, Department of Psychiatry, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran 2Department of Occupational Health Engineering, Faculty of Health, Qazvin University of Medical Sciences, Qazvin, Iran ABSTRACT Researchers showed comorbidity of sleep disorders and mental disorders. The current study aimed to evaluate depression and anxiety and their relationship with insomnia, nightmare and demographic variables in the medical students of Qazvin University of Medical Sciences in 2015. The study population included 253 medical students with the age range of 18-35 years. Data were gathered using Beck depression inventory, Cattle anxiety, and insomnia and nightmare questionnaires and were analyzed by proper statistical methods (independent T-test, Chi-square test and Spearman correlation coefficient (P<0.05). Among the participants, 126 (49.6%) subjects had depression and 108 (42.5%) anxiety. The prevalence of depression and anxiety among the subjects with lower family income was significantly higher (X2=6.75, P=.03 for depression and X2=27.99, P<0.05 for anxiety). There was a close relationship between depression with sleep-onset difficulty, difficulty in awakening and daily sleep attacks, and also between anxiety with sleep-onset difficulty and daily tiredness (P <0.05). In addition, there was a close relationship between depression and anxiety with nightmare; 16.2% of the subjects with depression and 26.5% of the ones with anxiety experienced nightmares.
    [Show full text]
  • Sleeping Disorders and Anxiety in Academicians: a Comparative Analysis
    Original Article / Özgün Makale DO I: 10.4274/jtsm.43153 Journal of Turkish Sleep Medicine 2018;5:86-90 Sleeping Disorders and Anxiety in Academicians: A Comparative Analysis Akademisyenlerde Uyku Bozuklukları ve Kaygı: Karşılaştırmalı Bir Analiz Nimet İlke Akçay, Anthony Awode, Mariyam Sohail, Yeliz Baybar, Kamal Alweithi, Milad Mahmoud Alilou, Mümtaz Güran Eastern Mediterranean University Faculty of Medicine, North Cyprus, Turkey Abstract Öz Objective: This study aims to examine the relationship between anxiety Amaç: Bu çalışma kaygı ve uyku bozuklukları arasındaki ilişkinin and sleep disorders and also to investigate the frequency of sleep irdelenmesini ve kaygı bozukluğu olanlarda uyku bozukluklarının disorders those with anxiety disorders among academicians who is a sıklığının kısıtlı bir çalışma grubu olan akademisyenlerde incelenmesini limited study group. hedeflemektedir. Materials and Methods: Two hundred and fifty academicians from Gereç ve Yöntem: Kampüsümüzdeki farklı fakültelerden 250 different faculties across our campus participated in the study with a akademisyen %47 erkek ve %53 kadın cinsiyet dağılımı ile çalışmaya gender distribution of 47% males and 53% females. The study was dahil edilmiştir. Çalışmada (i) demografik bilgiler, (ii) uyku evreleri ve conducted by a combined questionnaire which has four sections uyku kalitesi taraması, (iii) uyku bozukluklarının ölçeklendirilmesi, ve about (i) demographic information, (ii) sleep stages and sleep quality (iv) kaygı ölçeği olmak üzere 4 bölümden oluşan birleştirilmiş bir anket screening, (iii) scaling of sleep disorders and (iv) scale of anxiety. formu kullanılmıştır. Results: Anxiety in female and male participants was found to be 59% Bulgular: Kadın ve erkek popülasyonda kaygı sırası ile %59 ve %41 and 41% respectively. The total score of anxiety scale was positively olarak belirlenmiştir.
    [Show full text]
  • Lucid Dreaming and the Feeling of Being Refreshed in the Morning: a Diary Study
    Article Lucid Dreaming and the Feeling of Being Refreshed in the Morning: A Diary Study Michael Schredl 1,* , Sophie Dyck 2 and Anja Kühnel 2 1 Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Zentralinstitut für Seelische Gesundheit, J5, 68159 Mannheim, Germany 2 Department of Psychology, Medical School Berlin, Calandrellistraße 1-9, 12247 Berlin, Germany * Correspondence: [email protected]; Tel.: +49-621-1703-1782 Received: 15 December 2019; Accepted: 10 February 2020; Published: 12 February 2020 Abstract: REM periods with lucid dreaming show increased brain activation, especially in the prefrontal cortex, compared to REM periods without lucid dreaming and, thus, the question of whether lucid dreaming interferes with the recovery function of sleep arises. Cross-sectional studies found a negative relationship between sleep quality and lucid dreaming frequency, but this relationship was explained by nightmare frequency. The present study included 149 participants keeping a dream diary for five weeks though the course of a lucid dream induction study. The results clearly indicate that there is no negative effect of having a lucid dream on the feeling of being refreshed in the morning compared to nights with the recall of a non-lucid dream; on the contrary, the feeling of being refreshed was higher after a night with a lucid dream. Future studies should be carried out to elicit tiredness and sleepiness during the day using objective and subjective measurement methods. Keywords: lucid dreaming; sleep quality; nightmares 1. Introduction Lucid dreams are defined as dreams in which the dreamer is aware that he or she is dreaming [1].
    [Show full text]
  • Sedative Hypnotics
    Louisiana Medicaid Sedative Hypnotics The Louisiana Uniform Prescription Drug Prior Authorization Form should be utilized to request: • Prior authorization for non-preferred sedative hypnotics; OR • Clinical authorization for tasimelteon (Hetlioz®, Hetlioz LQ™). Additional Point-of-Sale edits may apply. Some of tThese agents may have Black Box Warnings and/or may be subject to Risk Evaluation and Mitigation Strategy (REMS) under FDA safety regulations. Please refer to individual prescribing information for details. ___________________________________________________________________________________ Non-Preferred Agents Approval Criteria for Initial and Reauthorization Requests • There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc.; AND • The requested medication has been prescribed for an approved diagnosis (if applicable); AND • Previous use of a preferred product - ONE of the following is required: o The recipient has had a treatment failure with at least one preferred product; OR o The recipient has had an intolerable side effect to at least one preferred product; OR o The recipient has documented contraindication(s) to all of the preferred products that are appropriate to use for the condition being treated; OR o There is no preferred product that is appropriate to use for the condition being treated; AND • By submitting the authorization request, the prescriber attests to the following: o The prescribing information for the requested medication has been thoroughly reviewed, including
    [Show full text]
  • Physiological and Psychological Measurement of Sleep Disturbance in Female Trauma Survivors with PTSD and Major Depression
    University of Missouri, St. Louis IRL @ UMSL Dissertations UMSL Graduate Works 7-25-2013 Physiological and Psychological Measurement of Sleep Disturbance in Female Trauma Survivors with PTSD and Major Depression Kimberly Borkowski Werner University of Missouri-St. Louis Follow this and additional works at: https://irl.umsl.edu/dissertation Part of the Psychology Commons Recommended Citation Werner, Kimberly Borkowski, "Physiological and Psychological Measurement of Sleep Disturbance in Female Trauma Survivors with PTSD and Major Depression" (2013). Dissertations. 306. https://irl.umsl.edu/dissertation/306 This Dissertation is brought to you for free and open access by the UMSL Graduate Works at IRL @ UMSL. It has been accepted for inclusion in Dissertations by an authorized administrator of IRL @ UMSL. For more information, please contact [email protected]. SLEEP DISTURBANCE IN FEMALES WITH PTSD AND DEPRESSION 1 Physiological and Psychological Measurement of Sleep Disturbance in Female Trauma Survivors with PTSD and Major Depression Kimberly B. Werner M.A, Psychology – Behavioral Neuroscience, University of Missouri – St. Louis, 2009 B.A., Psychology, Saint Louis University, 2006 A Dissertation Submitted at the University of Missouri – St. Louis in partial fulfillment of the requirements for the degree Doctor of Philosophy in Psychology with an emphasis in Behavioral Neuroscience June 2013 Advisory Committee: Dr. Michael G. Griffin, Ph.D. Chairperson Dr. Tara E. Galovski, Ph.D. Dr. Joseph M. Ojile MD, D.ABSM, FCCP Dr. George Taylor, Ph.D.
    [Show full text]
  • New Drug Evaluation Monograph Template
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Abbreviated Class Update: Newer Drugs for Insomnia Month/Year of Review: November 2014 End date of literature search: August Week 3 2014 New drug(s): tasimelteon (Hetlioz™) Manufacturer: Vanda Pharmaceuticals Inc. suvorexant (Belsomra™) Merck & Co., Inc. Current Status of Preferred Drug List (PDL) Class: Preferred Agents: ZOLPIDEM TABLET Non Preferred Agents: ZALEPLON CAPSULE, ZOLPIDEM EXTENDED-RELEASE TABLET, ZOLPIMIST™, LUNESTA™, ROZEREM™, SILENOR™, EDULAR™, INTERMEZZO™ Prior Authorization (PA) Criteria: A quantity limit is in place to prevent chronic daily use of all sedatives (Appendix 2) and to determine if the diagnosis is funded. Treatment of sleep disorders without sleep apnea is not a funded diagnosis (Line 636) by Oregon Health Plan (OHP). Treatment of insomnia contributing to a covered comorbid condition is funded. Electronic step edits were incorporated into the PA process as recommended at the March 2014 P&T meeting to streamline this process. There is also a PA required to prevent a patient from receiving two concurrent oral sedative medications. Research Questions: Is there new comparative effectiveness or safety evidence since the last scan (literature search end date of Week 2, June 2013) of newer drugs for insomnia to warrant a change to the preferred drug list (PDL)? Is there evidence that tasimelteon or suvorexant is more effective or safer than currently available newer drugs for insomnia? Is there evidence that tasimelteon or suvorexant is more effective of safer for a sub-set of patients with insomnia? Conclusions: There is no new comparative evidence for newer drugs for insomnia since the last scan.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Sleep Disturbances in Patients with Persistent Delusions: Prevalence, Clinical Associations, and Therapeutic Strategies
    Review Sleep Disturbances in Patients with Persistent Delusions: Prevalence, Clinical Associations, and Therapeutic Strategies Alexandre González-Rodríguez 1 , Javier Labad 2 and Mary V. Seeman 3,* 1 Department of Mental Health, Parc Tauli University Hospital, Autonomous University of Barcelona (UAB), I3PT, Sabadell, 08280 Barcelona, Spain; [email protected] 2 Department of Psychiatry, Hospital of Mataró, Consorci Sanitari del Maresme, Institut d’Investigació i Innovació Parc Tauli (I3PT), CIBERSAM, Mataró, 08304 Barcelona, Spain; [email protected] 3 Department of Psychiatry, University of Toronto, #605 260 Heath St. West, Toronto, ON M5T 1R8, Canada * Correspondence: [email protected] Received: 1 September 2020; Accepted: 12 October 2020; Published: 16 October 2020 Abstract: Sleep disturbances accompany almost all mental illnesses, either because sound sleep and mental well-being share similar requisites, or because mental problems lead to sleep problems, or vice versa. The aim of this narrative review was to examine sleep in patients with delusions, particularly in those diagnosed with delusional disorder. We did this in sequence, first for psychiatric illness in general, then for psychotic illnesses where delusions are prevalent symptoms, and then for delusional disorder. The review also looked at the effect on sleep parameters of individual symptoms commonly seen in delusional disorder (paranoia, cognitive distortions, suicidal thoughts) and searched the evidence base for indications of antipsychotic drug effects on sleep. It subsequently evaluated the influence of sleep therapies on psychotic symptoms, particularly delusions. The review’s findings are clinically important. Delusional symptoms and sleep quality influence one another reciprocally. Effective treatment of sleep problems is of potential benefit to patients with persistent delusions, but may be difficult to implement in the absence of an established therapeutic relationship and an appropriate pharmacologic regimen.
    [Show full text]
  • Specialty Pharmacy Program Drug List
    Specialty Pharmacy Program Drug List The Specialty Pharmacy Program covers certain drugs commonly referred to as high-cost Specialty Drugs. To receive in- network benefits/coverage for these drugs, these drugs must be dispensed through a select group of contracted specialty pharmacies or your medical provider. Please call the BCBSLA Customer Service number on the back of your member ID card for information about our contracted specialty pharmacies. All specialty drugs listed below are limited to the retail day supply listed in your benefit plan (typically a 30-day supply). As benefits may vary by group and individual plans, the inclusion of a medication on this list does not imply prescription drug coverage. Please refer to your benefit plan for a complete list of benefits, including specific exclusions, limitations and member cost-sharing amounts you are responsible for such as a deductible, copayment and coinsurance. Brand Name Generic Name Drug Classification 8-MOP methoxsalen Psoralen ACTEMRA SC tocilizumab Monoclonal Antibody/Arthritis ACTHAR corticotropin Adrenocortical Insufficiency ACTIMMUNE interferon gamma 1b Interferon ADCIRCA tadalafil Pulmonary Vasodilator ADEMPAS riociguat Pulmonary Vasodilator AFINITOR everolimus Oncology ALECENSA alectinib Oncology ALKERAN (oral) melphalan Oncology ALUNBRIG brigatinib Oncology AMPYRA ER dalfampridine Multiple Sclerosis APTIVUS tipranavir HIV/AIDS APOKYN apomorphine Parkinson's Disease ARCALYST rilonacept Interleukin Blocker/CAPS ATRIPLA efavirenz-emtricitabine-tenofovir HIV/AIDS AUBAGIO
    [Show full text]
  • Can We Induce Lucid Dreams? a Pharmacological Point of View Firas Hasan Bazzari Faculty of Pharmacy, Cairo University, Cairo, Egypt
    A pharmacological view on lucid dream induction I J o D R Can we induce lucid dreams? A pharmacological point of view Firas Hasan Bazzari Faculty of Pharmacy, Cairo University, Cairo, Egypt Summary. The phenomenon of lucid dreaming, in which an individual has the ability to be conscious and in control of his dreams, has attracted the public attention, especially in the era of internet and social media platforms. With its huge pop- ularity, lucid dreaming triggered passionate individuals, particularly lucid dreamers, to spread their thoughts and experi- ences in lucid dreaming, and provide a number of tips and techniques to induce lucidity in dreams. Scientific research in the field of sleep and dreams has verified the phenomenon of lucid dreaming for decades. Nevertheless, various aspects regarding lucid dreaming are not fully understood. Many hypotheses and claims about lucid dreaming induction are yet to be validated, and at present lucid dreaming still lacks efficient and reliable induction methods. Understanding the molecular basis, brain physiology, and underlying mechanisms involved in lucid dreaming can aid in developing novel and more target-specific induction methods. This review will focus on the currently available scientific findings regarding neurotransmitters’ behavior in sleep, drugs observed to affect dreams, and proposed supplements for lucid dreaming, in order to discuss the possibility of inducing lucid dreams from a pharmacological point of view. Keywords: Lucid dreaming, Dreams, REM sleep, Neurotransmitters, Supplements, Pharmacology of lucid dreaming. 1. Introduction different methods and labeled according to the method’s success rate in inducing lucid dreams. Techniques, such as Lucid dreaming is a unique psychological phenomenon in mnemonic induced lucid dreams (MILD), reflection/reality which a dreaming individual is aware that he/she is dreaming testing, Tholey’s combined technique, light stimulus, and (Voss, 2010).
    [Show full text]
  • Parasomnias Fact Sheet
    Fact Sheet Parasomnias Overview Parasomnias are unusual things we do or experience while asleep or while partially asleep. Almost everyone has a nightmare from time to time. When someone has nightmares frequently, and they are very distressed about them, they may have Nightmare Disorder. Nightmare Disorder is considered a parasomnia since it is an unpleasant event that occurs while asleep. The term parasomnia is much broader than nightmares, and a person with Nightmare Disorder has more than just the occasional nightmare event. In addition to Nightmare Disorder, other common parasomnia events include: REM Behavior Disorder (RBD) Sleep paralysis Sleepwalking Confusional arousals What are common parasomnias? Typically parasomnias are classified by whether they occur during the rapid eye movement (REM) sleep or Non- REM sleep. People with an REM parasomnia are more likely to recall their unusual sleep behaviors (for example, nightmare) than those with a Non-REM parasomnia (for example, sleepwalking). REM Behavior Disorder (RBD) Most dreaming occurs in REM sleep. During REM sleep, most of our body muscles are paralyzed to prevent us from acting out our dreams. In REM Behavior Disorder (RBD), a person does not have this protective paralysis during REM sleep. Therefore, they might “act out” their dream. Since dreams may involve violence and protecting oneself, a person acting out their dream may injure themselves or their bed partner. The person will usually recall the dream, but not realize that they were actually moving while asleep. Sleep Paralysis and Sleep Hallucinations During REM sleep our muscles are paralyzed to keep us from acting out our dreams.
    [Show full text]
  • Tasimelteon (Hetlioz) for Treatment of Non–24-Hour Sleep-Wake Disorder
    AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 08: Functional Limitations and Disability Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290-2010-00006-C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 June 2015 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290-2010-00006-C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. This report’s content should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual topic profiles are developed for technologies and programs that appear to be close to diffusion into practice in the United States. Those reports are sent to various experts with clinical, health systems, health administration, and/or research backgrounds for comment and opinions about potential for impact. The comments and opinions received are then considered and synthesized by ECRI Institute to identify interventions that experts deemed, through the comment process, to have potential for high impact. Please see the methods section for more details about this process.
    [Show full text]